Compare Cassava Sciences Inc (FLNA) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $40.511, up 4.87% over the past 24 hours. The technical outlook is neutral with mixed signals from moving averages and oscillators, while support and resistance levels are tightly clustered. As a leveraged inverse ETF designed to deliver -3x the daily return of the Nasdaq-100, it carries inherent structural risks and is unsuitable for long-term holding due to daily reset mechanics that can erode value over time.

The outlook for SQQQ remains highly speculative and tactical. It may offer short-term hedging benefits against Nasdaq-100 declines but presents severe long-term erosion risks. Investors should strictly limit exposure to sophisticated, active traders who can closely monitor market timing, as its performance is entirely dependent on short-term directional bets against the tech sector.